Nuclear translocation of STAT3 and NF-κB are independent of each other but NF-κB supports expression and activation of STAT3

Cellular Signalling

Volumn 32, Issue , 2017, Pages 36-47

  Martincuks, Antons ^a   Andryka, Katarzyna ^b   Küster, Andrea ^a   Schmitz Van de Leur, Hildegard ^a   Komorowski, Michal ^b   Müller Newen, Gerhard ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b INSTITUTE OF FUNDAMENTAL TECHNOLOGICAL RESEARCH   (Poland)

Author keywords

Crosstalk; NF B; Nuclear translocation; Signal transduction; STAT3

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; STAT1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; STAT5 PROTEIN;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; BIOACCUMULATION; CELL LINE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HELA CELL LINE; MEF CELL LINE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RELIABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PROTEIN TRANSPORT;

ANIMALS; CELL NUCLEUS; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; MICE; NF-KAPPA B; PROTEIN TRANSPORT; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85009841534     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2017.01.006     Document Type: Article

References (65)

1. [1] Levy, D.E., Darnell, J.E. Jr., Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3 (2002), 651–662.
2. [2] Levy, D.E., Lee, C.K., What does Stat3 do?. J. Clin. Invest. 109 (2002), 1143–1148.
3. [3] Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Müller-Newen, G., Schaper, F., Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374 (2003), 1–20.
4. [4] Haspel, R.L., Salditt-Georgieff, M., Darnell, J.E. Jr., The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J. 15 (1996), 6262–6268.
5. [5] Bhattacharya, S., Schindler, C., Regulation of Stat3 nuclear export. J. Clin. Invest. 111 (2003), 553–559.
6. [6] Pranada, A.L., Metz, S., Herrmann, A., Heinrich, P.C., Müller-Newen, G., Real time analysis of STAT3 nucleocytoplasmic shuttling. J. Biol. Chem. 279 (2004), 15114–15123.
7. [7] Herrmann, A., Vogt, M., Mönnigmann, M., Clahsen, T., Sommer, U., Haan, S., et al. Nucleocytoplasmic shuttling of persistently activated STAT3. J. Cell Sci. 120 (2007), 3249–3261.
8. [8] Naugler, W.E., Karin, M., The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 14 (2008), 109–119.
9. [9] Yu, H., Pardoll, D., Jove, R., STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9 (2009), 798–809.
10. [10] Vallabhapurapu, S., Karin, M., Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 27 (2009), 693–733.
11. [11] Hayden, M.S., Ghosh, S., Shared principles in NF-kappaB signaling. Cell 132 (2008), 344–362.
12. [12] Natoli, G., De Santa, F., Shaping alternative NF-kappaB-dependent gene expression programs: new clues to specificity. Cell Death Differ. 13 (2006), 693–696.
13. [13] Arenzana-Seisdedos, F., Turpin, P., Rodriguez, M., Thomas, D., Hay, R.T., Virelizier, J.L., et al. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J. Cell Sci. 110:Pt 3 (1997), 369–378.
14. [14] Chen, L., Fischle, W., Verdin, E., Greene, W.C., Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293 (2001), 1653–1657.
15. [15] Grivennikov, S.I., Karin, M., Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21 (2010), 11–19.
16. [16] Grivennikov, S.I., Karin, M., Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann. Rheum. Dis. 70:Suppl. 1 (2011), i104–i108.
17. [17] Bode, J.G., Albrecht, U., Haussinger, D., Heinrich, P.C., Schaper, F., Hepatic acute phase proteins—regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-kappaB-dependent signaling. Eur. J. Cell Biol. 91 (2012), 496–505.
18. [18] Bollrath, J., Greten, F.R., IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep. 10 (2009), 1314–1319.
19. [19] Debidda, M., Wang, L., Zang, H., Poli, V., Zheng, Y., A role of STAT3 in Rho GTPase-regulated cell migration and proliferation. J. Biol. Chem. 280 (2005), 17275–17285.
20. [20] Zouein, F.A., Duhe, R.J., Arany, I., Shirey, K., Hosler, J.P., Liu, H., et al. Loss of STAT3 in mouse embryonic fibroblasts reveals its Janus-like actions on mitochondrial function and cell viability. Cytokine 66 (2014), 7–16.
21. [21] Kulesza, D.W., Carre, T., Chouaib, S., Kaminska, B., Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFalpha- and NK cytotoxicity. Exp. Cell Res. 319 (2013), 506–516.
22. [22] McFarland, B.C., Gray, G.K., Nozell, S.E., Hong, S.W., Benveniste, E.N., Activation of the NF-kappaB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells. Mol. Cancer Res. 11 (2013), 494–505.
23. [23] Grabner, B., Schramek, D., Mueller, K.M., Moll, H.P., Svinka, J., Hoffmann, T., et al. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat. Commun., 6, 2015, 6285.
24. [24] Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. U.S.A. 94 (1997), 3801–3804.
25. [25] Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., Akira, S., Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 161 (1998), 4652–4660.
26. [26] Alonzi, T., Maritano, D., Gorgoni, B., Rizzuto, G., Libert, C., Poli, V., Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol. Cell. Biol. 21 (2001), 1621–1632.
27. [27] Costa-Pereira, A.P., Tininini, S., Strobl, B., Alonzi, T., Schlaak, J.F., Is'harc, H., et al. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 8043–8047.
28. [28] Moreno, R., Sobotzik, J.M., Schultz, C., Schmitz, M.L., Specification of the NF-kappaB transcriptional response by p65 phosphorylation and TNF-induced nuclear translocation of IKK epsilon. Nucleic Acids Res. 38 (2010), 6029–6044.
29. [29] Arcone, R., Pucci, P., Zappacosta, F., Fontaine, V., Malorni, A., Marino, G., et al. Single-step purification and structural characterization of human interleukin-6 produced in Escherichia coli from a T7 RNA polymerase expression vector. Eur. J. Biochem. 198 (1991), 541–547.
30. [30] Weiergräber, O., Hemmann, U., Küster, A., Müller-Newen, G., Schneider, J., Rose-John, S., et al. Soluble human interleukin-6 receptor: expression in insect cells, purification and characterization. Eur. J. Biochem. 234 (1995), 661–669.
31. [31] Suthaus, J., Tillmann, A., Lorenzen, I., Bulanova, E., Rose-John, S., Scheller, J., Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth. Mol. Biol. Cell 21 (2010), 2797–2807.
32. [32] Tay, S., Hughey, J.J., Lee, T.K., Lipniacki, T., Quake, S.R., Covert, M.W., Single-cell NF-kappaB dynamics reveal digital activation and analogue information processing. Nature 466:7303 (2010), 267–271.
33. [33] Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001), 402–408.
34. [34] Vogt, M., Domoszlai, T., Kleshchanok, D., Lehmann, S., Schmitt, A., Poli, V., et al. The role of the N-terminal domain in dimerization and nucleocytoplasmic shuttling of latent STAT3. J. Cell Sci. 124 (2011), 900–909.
35. [35] Blaecke, A., Delneste, Y., Herbault, N., Jeannin, P., Bonnefoy, J.Y., Beck, A., et al. Measurement of nuclear factor-kappa B translocation on lipopolysaccharide-activated human dendritic cells by confocal microscopy and flow cytometry. Cytometry 48 (2002), 71–79.
36. [36] Schnell, U., Dijk, F., Sjollema, K.A., Giepmans, B.N., Immunolabeling artifacts and the need for live-cell imaging. Nat. Methods 9 (2012), 152–158.
37. [37] Yang, J., Liao, X., Agarwal, M.K., Barnes, L., Auron, P.E., Stark, G.R., Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 21 (2007), 1396–1408.
38. [38] Adli, M., Baldwin, A.S., IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J. Biol. Chem. 281 (2006), 26976–26984.
39. [39] Dong, J., Jimi, E., Zhong, H., Hayden, M.S., Ghosh, S., Repression of gene expression by unphosphorylated NF-kappaB p65 through epigenetic mechanisms. Genes Dev. 22:9 (2008), 1159–1173.
40. [40] Vekemans, K., Rosseel, L., Wisse, E., Braet, F., Immuno-localization of Fas and FasL in rat hepatic endothelial cells: influence of different fixation protocols. Micron 35 (2004), 303–306.
41. [41] Ray, S., Boldogh, I., Brasier, A.R., STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen. Gastroenterology 129 (2005), 1616–1632.
42. [42] Liu, L., McBride, K.M., Reich, N.C., STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 8150–8155.
43. [43] Martincuks, A., Fahrenkamp, D., Haan, S., Herrmann, A., Küster, A., Müller-Newen, G., Dissecting functions of the N-terminal domain and GAS-site recognition in STAT3 nuclear trafficking. Cell. Signal., 2016.
44. [44] Li, M.W., Zhou, L., Lam, H.M., Paraformaldehyde fixation may lead to misinterpretation of the subcellular localization of plant high mobility group box proteins. PLoS One, 10, 2015, e0135033.
45. [45] Smith-Clerc, J., Hinz, B., Immunofluorescence detection of the cytoskeleton and extracellular matrix in tissue and cultured cells. Methods Mol. Biol. 611 (2010), 43–57.
46. [46] Pollice, A.A., McCoy, J.P. Jr., Shackney, S.E., Smith, C.A., Agarwal, J., Burholt, D.R., et al. Sequential paraformaldehyde and methanol fixation for simultaneous flow cytometric analysis of DNA, cell surface proteins, and intracellular proteins. Cytometry 13 (1992), 432–444.
47. [47] Brock, R., Hamelers, I.H., Jovin, T.M., Comparison of fixation protocols for adherent cultured cells applied to a GFP fusion protein of the epidermal growth factor receptor. Cytometry 35 (1999), 353–362.
48. [48] Buss, H., Dorrie, A., Schmitz, M.L., Hoffmann, E., Resch, K., Kracht, M., Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK[60], IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J. Biol. Chem. 279 (2004), 55633–55643.
49. [49] Schmitz, M.L., Mattioli, I., Buss, H., Kracht, M., NF-kappaB: a multifaceted transcription factor regulated at several levels. Chembiochem 5 (2004), 1348–1358.
50. [50] Scott, M.L., Fujita, T., Liou, H.C., Nolan, G.P., Baltimore, D., The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Genes Dev. 7 (1993), 1266–1276.
51. [51] Yu, Z., Zhang, W., Kone, B.C., Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem. J. 367 (2002), 97–105.
52. [52] Agrawal, A., Cha-Molstad, H., Samols, D., Kushner, I., Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology 108 (2003), 539–547.
53. [53] Hagihara, K., Nishikawa, T., Sugamata, Y., Song, J., Isobe, T., Taga, T., et al. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells 10 (2005), 1051–1063.
54. [54] Dhar, K., Rakesh, K., Pankajakshan, D., Agrawal, D.K., SOCS3 promotor hypermethylation and STAT3-NF-kappaB interaction downregulate SOCS3 expression in human coronary artery smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 304 (2013), H776–H785.
55. [55] Guo, A.K., Hou, Y.Y., Hirata, H., Yamauchi, S., Yip, A.K., Chiam, K.H., et al. Loss of p53 enhances NF-kappaB-dependent lamellipodia formation. J. Cell. Physiol. 229 (2014), 696–704.
56. [56] Bernier, M., Paul, R.K., Martin-Montalvo, A., Scheibye-Knudsen, M., Song, S., He, H.J., et al. Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein. J. Biol. Chem. 286 (2011), 19270–19279.
57. [57] Anrather, J., Racchumi, G., Iadecola, C., cis-Acting, element-specific transcriptional activity of differentially phosphorylated nuclear factor-kappa B. J. Biol. Chem. 280:1 (2005), 244–252.
58. [58] Zhong, H., Voll, R.E., Ghosh, S., Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell 1 (1998), 661–671.
59. [59] Sasaki, C.T., Issaeva, N., Vageli, D.P., In vitro model for gastroduodenal reflux-induced nuclear factor-kappaB activation and its role in hypopharyngeal carcinogenesis. Head Neck, 2015.
60. [60] Haan, S., Keller, J.F., Behrmann, I., Heinrich, P.C., Haan, C., Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation. Cell. Signal. 17:12 (2005), 1542–1550.
61. [61] Kramer, O.H., Baus, D., Knauer, S.K., Stein, S., Jager, E., Stauber, R.H., et al. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 20 (2006), 473–485.
62. [62] Świerkot, J., Nowak, B., Czarny, A., Zaczyńska, E., Sokolik, R., Madej, M., Korman, L., Sebastian, A., Wojtala, P., Lubiński, Ł., Wiland, P., The activity of JAK/STAT and NF-κB in patients with rheumatoid arthritis. Adv. Clin. Exp. Med. 25:4 (2016), 709–717.
63. [63] Kim, H.S., Kim, D.C., Kim, H.M., Kwon, H.J., Kwon, S.J., Kang, S.J., et al. STAT1 deficiency redirects IFN signalling toward suppression of TLR response through a feedback activation of STAT3. Sci. Rep., 5, 2015, 13414.
64. [64] Xu, Q.Q., Zhou, Q., Xu, L.L., Lin, H., Wang, X.J., Ma, W.L., et al. Toll-like receptor 4 signaling inhibits malignant pleural effusion by altering Th1/Th17 responses. Cell Biol. Int. 39 (2015), 1120–1130.
65. [65] Guzzo, C., Che Mat, N.F., Gee, K., Interleukin-27 induces a STAT1/3- and NF-kappaB-dependent proinflammatory cytokine profile in human monocytes. J. Biol. Chem. 285 (2010), 24404–24411.